Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

Outrun Therapeutics Scotland

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areasWill drive application of Outrun's novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligasesContinues strong momentum following 2024 emergence from stealth with $10M seed financingView original content:https://www.prnewswire.co.uk/news-releases/outrun-therapeutics-expands-leadership-team-with-appointment-of-matthew-fyfe-as-chief-scientific-officer-302348196.html